BELGRADE, Mont. , Sept. 1, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, Inc. , will exhibit at EUROSPINE 2015.

BELGRADE, Mont. , Aug. 27, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), formerly Bacterin International Holdings, Inc. , a leader in the development of class-leading regenerative medicine products and medical devices, today announced that its Chief Executive Officer, Dan

BELGRADE, Mont. , Aug. 25, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, Bacterin International, Inc.

First Half Xtant(TM) Medical Pro Forma Combined 2015 Highlights: On July 31, 2015 , the Company announced the close of its acquisition of X-spine Systems, Inc. Pro forma combined revenue increased 12.6% to $43.4 million from $38.5 million in the first half of 2014 Pro forma gross profit increased

BELGRADE, Mont., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. ( BONE ), a leader in the development of revolutionary bone graft material, today announced that it will release its financial results for the period ended June 30, 2015, at the close of the financial markets on August

BELGRADE, Mont. , July 31, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, has announced the closing of its previously announced offering of $65 million aggregate principal amount of convertible senior

Combines Bacterin's Strength in Orthobiologics With X-spine's Expertise in Hardware Offering Complementary Product Lines Focused on Orthopedic and Spine Surgical Procedures BELGRADE, Mont. , July 31, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc.

BELGRADE, Mont. , July 27, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, has announced the pricing of $65 million aggregate principal amount of convertible senior unsecured notes due 2021 (the "Notes").

Combines Bacterin's strength in orthobiologics with X-spine's expertise in hardware offering complementary product lines focused on orthopedic and spine surgical procedures. Pro forma revenue and EBITDA for the combined company for the 12 months ended December 31, 2014 was approximately $77.5

Second Quarter Total Revenue in the Range of $10.0 Million to $10.2 Million, an Increase of Approximately 12-15% Over the Same Period Last Year. BELGRADE, Mont. , July 9, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone